ArticleCureus2026
Pembrolizumab and Enfortumab-Induced Immunotherapy Myocarditis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 64-year-old male with coronary artery disease, hypertension, hyperlipidemia, obstructive sleep apnea, and right ureteral urothelial carcinoma presented with chest pain, neck weakness, and myalgias after his first cycle of pembrolizumab and enfortumab vedotin. He developed a non-ST-segment elevation myocardial infarction (NSTEMI) alongside suspected immune checkpoint inhibitor (ICI)-associated myocarditis and myositis. Initial tests showed elevated troponin at 568 ng/L, creatinine phosphokinase (CPK) at 3,332 U/L, and transaminases. ECG revealed anterolateral ST-segment depression and left anterior fascicular block. Cardiac catheterization confirmed 90% mid-left anterior descending (LAD) artery stenosis, treated with a drug-eluting stent, and endomyocardial biopsy verified focal moderate lymphocytic myocarditis with myocyte necrosis. Treatment with high-dose methylprednisolone and intravenous immunoglobulin led to improvement in symptoms, biomarkers, and cardiac function. He was discharged on prednisone taper, dual antiplatelet therapy, anticoagulation, and prophylaxis, with outpatient follow-up arranged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.